Finance

Beta
Lists
006280:KRX
GC Biopharma Corp
â‚©122,100.00
-0.97%
(-1,200.00) 1D
Jun 10, 3:30:30 PM GMT+9  ·   KRW
All symbols
SymbolPriceChange% Change
Generating top insights for 006280...
Open
â‚©120,500
High
â‚©123,400
Low
â‚©119,000
Mkt. cap
1.43T
Avg. vol.
72.55K
Volume
31.18K
Dividend
1.23%
Quarterly dividend
â‚©375
Ex-dividend date
Mar 30, 2026
52-wk high
â‚©183,800
52-wk low
â‚©117,800
EPS
-â‚©1,218
Shares outstanding
11.69M
No. of employees
2K
Open
â‚©120,500
High
â‚©123,400
Low
â‚©119,000
Mkt. cap
1.43T
Avg. vol.
72.55K
Volume
31.18K
Dividend
1.23%
Quarterly dividend
â‚©375
Ex-dividend date
Mar 30, 2026
52-wk high
â‚©183,800
52-wk low
â‚©117,800
EPS
-â‚©1,218
Shares outstanding
11.69M
No. of employees
2K
News stories
From sources across the web
Profile
GC Biopharma is a biopharmaceutical company headquartered in Yongin, South Korea. Wikipedia
About GC Biopharma Corp
CEOEun Chul Huh | Il-sup Huh
Employees2.01K
FoundedOct 5, 1967
Headquarters-
SectorBiotechnology
Previous reportsAll values in KRW
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in KRW
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
500.26B
609.49B
497.75B
435.53B
Cost of goods sold
345.44B
463.97B
357.85B
313.13B
Cost of revenue
345.44B
463.97B
357.85B
313.13B
Research and development expenses
38.09B
33.48B
44.81B
35.32B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
84.42B
77.09B
83.01B
70.35B
Operating expense
128.79B
116.30B
135.30B
110.67B
Total operating expenses
474.23B
580.27B
493.15B
423.80B
Operating income
26.03B
29.21B
4.60B
11.73B
Other non operating income
-1.58B
13.04M
636.32M
-10.15B
EBT including unusual items
33.14B
24.89B
-110.07B
28.59B
EBT excluding unusual items
43.14B
21.52B
-4.39B
25.91B
Income tax expense
453.89M
6.74B
-7.27B
8.45B
Effective tax rate
1.37%
27.07%
6.61%
29.56%
Other operating expenses
302.00M
296.00M
306.00M
590.00M
Net income
37.99B
15.95B
-88.30B
20.47B
Net profit margin
7.59%
2.62%
-17.74%
4.70%
Earnings per share
3.33K
1.40K
-
1.79K
Interest and investment income
859.53M
605.00M
623.00M
881.00M
Interest expense
-12.57B
-12.76B
-13.40B
-13.27B
Net interest expenses
-11.72B
-12.15B
-12.77B
-12.39B
Depreciation and amortization charges
1.75B
1.68B
2.17B
1.63B
EBITDA
49.78B
50.70B
24.79B
34.46B
Gain or loss from assets sale
-40.60B
-268.00M
1.01B
-35.56B
AI content may include mistakes. Learn more

Research

AI content may include mistakes. Learn more